Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Ultragenyx Pharmaceutical Inc. (RARE) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/10/2023 4 Horn Howard (CFO) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.
Txns: Granted 80,366 shares @ $0
Granted 140,469 options to buy @ $35.68, valued at $5M
10/10/2023 3 Horn Howard (CFO) has filed a Form 3 on Ultragenyx Pharmaceutical Inc.
09/29/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
09/29/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
08/03/2023 8-K Quarterly results
Docs: "Ultragenyx Reports Second Quarter 2023 Financial Results and Corporate Update Second quarter 2023 total revenue of $108.3 million, Crysvita® revenue of $83.0 million and Dojolvi® revenue of $16.5 million Total revenue grew 21% and total Crysvita revenue grew 20% versus the second quarter 2022 Reaffirmed 2023 expected total revenue guidance between $425 million to $450 million, Crysvita revenue of $325 million to $340 million, and Dojolvi revenue of $65 million to $75 million NOVATO, Calif. – Aug 03, 2023 – Ultragenyx Pharmaceutical Inc. , a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today reported its financial results for the quarter ended June 30, 2023 and provided its financial guidance fo..."
07/12/2023 8-K Quarterly results
07/06/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab for the Treatment of Osteogenesis Imperfecta Pivotal Phase 3 portion of Orbit study now enrolling approximately 195 pediatric and young adult patients Newly initiated Phase 3 Cosmic study now enrolling approximately 65 younger pediatric patients"
06/30/2023 144 Form 144 - Report of proposed sale of securities:
06/30/2023 4 Sanders Corazon (Corsee) D. (Director) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.
Txns: Sold 585 shares @ $46.76, valued at $27.4k
06/09/2023 4 Ray Amrit (Director) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.
Txns: Granted 3,860 shares @ $0
Granted 7,110 options to buy @ $51.82, valued at $368.4k
06/09/2023 4 Fust Matthew K (Director) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.
Txns: Granted 3,860 shares @ $0
Disposed/sold 3,300 shares @ $51.82, valued at $171k
Granted 7,110 options to buy @ $51.82, valued at $368.4k
06/09/2023 4 Sanders Corazon (Corsee) D. (Director) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.
Txns: Granted 3,860 shares @ $0
Sold 1,485 shares @ $51.65, valued at $76.7k
Granted 7,110 options to buy @ $51.82, valued at $368.4k
06/09/2023 4 SULIMAN SHEHNAAZ (Director) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.
Txns: Granted 3,860 shares @ $0
Granted 7,110 options to buy @ $51.82, valued at $368.4k
06/09/2023 4 NARACHI MICHAEL (Director) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.
Txns: Granted 3,860 shares @ $0
Granted 7,110 options to buy @ $51.82, valued at $368.4k
06/09/2023 4 Dunsire Deborah (Director) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.
Txns: Granted 3,860 shares @ $0
Granted 7,110 options to buy @ $51.82, valued at $368.4k
06/09/2023 4 WELCH DANIEL G (Director) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.
Txns: Granted 3,860 shares @ $0
Granted 7,110 options to buy @ $51.82, valued at $368.4k
06/08/2023 144 Form 144 - Report of proposed sale of securities:
06/08/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
05/19/2023 4 Pinion John Richard (See Remarks) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.
Txns: Sold 2,012 shares @ $50, valued at $100.6k
05/18/2023 144 Form 144 - Report of proposed sale of securities:
05/17/2023 8-K Other Events  Interactive Data
05/10/2023 4 Huizenga Theodore Alan (SVP, Chief Accounting Officer) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.
Txns: Exercised 3,000 options to buy @ $21, valued at $63k
05/05/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
05/04/2023 144 Form 144 - Report of proposed sale of securities:
05/04/2023 8-K Quarterly results
05/02/2023 4 Crombez Eric (EVP and Chief Medical Officer) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.
Txns: Granted 4,658 shares @ $0
Granted 8,362 options to buy @ $44.03, valued at $368.2k
05/02/2023 3 Crombez Eric (EVP and Chief Medical Officer) has filed a Form 3 on Ultragenyx Pharmaceutical Inc.
04/24/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/24/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/18/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/23/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/14/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
03/03/2023 4 Bedrosian Camille L (EVP and Chief Medical Officer) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.
Txns: Granted 2,663 shares @ $0
Sold 3,881 shares @ $45.25, valued at $175.6k
03/03/2023 4 Parschauer Karah Herdman (EVP and Chief Legal Officer) has filed a Form 4 on Ultragenyx Pharmaceutical Inc.
Txns: Granted 2,663 shares @ $0
Granted 22,000 shares @ $0
Sold 3,161 shares @ $45.25, valued at $143k
Granted 39,400 options to buy @ $45.65, valued at $1.8M
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy